Colistin: new lessons on an old antibiotic

Area of Science:

• Infectious Diseases
• Pharmacology
• Clinical Medicine

Background:

• Colistin re-emerged for treating carbapenem-resistant Gram-negative bacterial infections.
• Recent studies evaluate colistin's clinical utility and safety profile.
• Understanding colistin's role in modern antimicrobial therapy is crucial.

Purpose of the Study:

• To review and summarize recent clinical studies on colistin's efficacy and safety.
• To assess colistin's comparative mortality and nephrotoxicity rates.
• To identify emerging challenges like colistin resistance.

Main Methods:

• Review of recent clinical studies on colistin.
• Analysis of mortality data compared to other treatments.
• Evaluation of nephrotoxicity rates and reversibility.
• Assessment of in vitro synergy data.

Main Results:

• Colistin associated with lower mortality than no treatment; higher unadjusted mortality than beta-lactams.
• Colistin primarily used in sicker patients with resistant infections.
• Nephrotoxicity rates not significantly higher; generally reversible.
• Emergence of colistin resistance noted in high-usage areas.
• In vitro synergy with carbapenems and rifampin reported.

Conclusions:

• Colistin remains a vital option for carbapenem-resistant Gram-negative infections.
• Careful patient selection and monitoring for resistance are essential.
• Ongoing randomized controlled trials will further clarify colistin's clinical role.